Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03774394 · ClinicalTrials.gov registry record · Phase 4
Impact of Chronic Kidney Disease on Clopidogrel Effects in Diabetes Mellitus
A Phase 4 study of Type 2 Diabetes Mellitus (T2DM) and Chronic Kidney Disease (CKD), sponsored by University of Florida.
- Completed
- Registry status
- Phase 4
- Development phase
- 61
- Enrollment target
- 1
- Study location
NCT03774394 is a Phase 4 study of Type 2 Diabetes Mellitus (T2DM) and Chronic Kidney Disease (CKD) that has completed, run by University of Florida. The registered enrollment target is 61 participants, below the 520-participant average among 24 other Type 2 Diabetes Mellitus (T2DM) trials with a reported enrollment target (88% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03774394, a Phase 4 study of Type 2 Diabetes Mellitus (T2DM) and Chronic Kidney Disease (CKD), has completed, sponsored by University of Florida.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 61 participants
- Enrollment target
- 1
- Study location
Study Summary
Patients with diabetes mellitus (DM) and chronic kidney disease (CKD) are at increased risk of atherothrombotic events. Clopidogrel is the most widely used platelet P2Y12 receptor inhibitor in patients with coronary artery disease (CAD). However, despite its benefits, many patients still experience recurrent atherothrombotic events. The proposed study will test the central hypothesis that in DM patients the presence of CKD reduces clopidogrel-mediated P2Y12 inhibitory effects through synergistic mechanisms, which include upregulation of the P2Y12 signaling pathway and impaired clopidogrel metabolism.
Conditions Studied
Interventions
- DRUG Clopidogrel
- DRUG Clopidogrel active metabolite
Study Locations (1)
Florida
- University of Florida Jacksonville - Jacksonville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 61 participants |
| Start Date | 2019-08-22 |
| Est. Completion | 2022-05-31 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03774394
The ClinicalTrials.gov registry entry for NCT03774394 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 61 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 520-participant average among 24 other Type 2 Diabetes Mellitus (T2DM) trials with a reported enrollment target (88% lower). The listed sponsor is University of Florida, which has 1,106 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Type 2 Diabetes Mellitus (T2DM) appearing as the primary indexed condition, and to 2 interventions - of which Clopidogrel is the first listed.
NCT03774394 reports 1 study location spanning 1 distinct geographic area - top geographies include Florida.
Frequently Asked Questions
What is clinical trial NCT03774394 about?
NCT03774394 is a clinical study titled "Impact of Chronic Kidney Disease on Clopidogrel Effects in Diabetes Mellitus". Patients with diabetes mellitus (DM) and chronic kidney disease (CKD) are at increased risk of atherothrombotic events. Clopidogrel is the most widely used platelet P2Y12 receptor inhibitor in patients with coronary artery disease (CAD). However, despite its benefits, many patients still experience ...
What is the current status of trial NCT03774394?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 61 participants. The study started on 2019-08-22. Estimated completion is 2022-05-31.
What conditions does trial NCT03774394 study?
This clinical trial studies the following conditions: Type 2 Diabetes Mellitus (T2DM), Chronic Kidney Disease (CKD), Coronary Artery Disease (CAD).
What interventions are being tested in trial NCT03774394?
The interventions under investigation include: Clopidogrel (DRUG), Clopidogrel active metabolite (DRUG).
Who is sponsoring clinical trial NCT03774394?
This trial is sponsored by University of Florida, which has 1,106 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03774394 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Type 2 Diabetes Mellitus (T2DM)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
CGM Adherence Compared to Finger-stick Glucose Monitoring in Pregnancies With Type 2 Pregestational Diabetes
RECRUITING · NA
-
Achieving Routine Intervention and Screening for Emotional Health
RECRUITING · NA
-
Evaluate Use of Tropocells(R) Autologous Platelet-rich Fibrin (PRF) for Wagner Grade 1 and Grade 2, Mild to Mod Neuroischemic Plantar Diabetic Foot Ulcer Wound Care.
RECRUITING · Phase 2
-
CGM for Management of Type 2 Diabetes in Pregnancy
RECRUITING · NA
-
Low-Dose Pioglitazone in Patients With NASH (AIM 2)
RECRUITING · Phase 2
-
Diabetes Electronic Prompt for Improved Care Coordination and Treatment in the ED
RECRUITING · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.